Search
Now showing items 191-200 of 4397
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
(2021-04-15)
Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the ...
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
(2016-04)
<h4>Background</h4>Bromodomain and extraterminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes. BET proteins bind acetylated histone ...
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
(2020-12)
Objectives: To report clinician-perceived changes to cancer service delivery in response to COVID-19. Design: Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical ...
Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer.
(2017-12)
Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for ...
Kinetic energy of He atoms in liquid He-4-He-3 mixtures
(AMER PHYSICAL SOC, 2003-12)
Deep inelastic neutron scattering measurements on liquid He-3-He-4 mixtures in the normal phase have been performed on the VESUVIO spectrometer at the ISIS pulsed neutron source at exchanged wave vectors of about qsimilar ...
Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks
(2017-02)
Evolution by natural selection is the conceptual foundation for nearly every branch of biology and increasingly also for biomedicine and medical research. In cancer biology, evolution explains how populations of cells in ...
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
(2017-03)
The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (<i>n</i> = 2,471) were randomly assigned to ...